

# Elliot Israel

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3578670/publications.pdf>

Version: 2024-02-01

103  
papers

6,931  
citations

81900

39  
h-index

62596

80  
g-index

104  
all docs

104  
docs citations

104  
times ranked

7842  
citing authors

#	ARTICLE	IF	CITATIONS
1	Interleukin-17 <sup>+</sup> producing innate lymphoid cells and the NLRP3 inflammasome facilitate obesity-associated airway hyperreactivity. <i>Nature Medicine</i> , 2014, 20, 54-61.	30.7	515
2	Unjamming and cell shape in the asthmatic airway epithelium. <i>Nature Materials</i> , 2015, 14, 1040-1048.	27.5	484
3	Severe and Difficult-to-Treat Asthma in Adults. <i>New England Journal of Medicine</i> , 2017, 377, 965-976.	27.0	357
4	Inflammatory and Comorbid Features of Patients with Severe Asthma and Frequent Exacerbations. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 195, 302-313.	5.6	346
5	Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction. <i>Journal of Clinical Investigation</i> , 2018, 128, 997-1009.	8.2	337
6	A role for the C3a anaphylatoxin receptor in the effector phase of asthma. <i>Nature</i> , 2000, 406, 998-1001.	27.8	330
7	Unsupervised phenotyping of Severe Asthma Research Program participants using expanded lung data. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 133, 1280-1288.	2.9	247
8	Effect of Vitamin D <sub>3</sub> on Asthma Treatment Failures in Adults With Symptomatic Asthma and Lower Vitamin D Levels. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 2083.	7.4	236
9	Randomised, placebo controlled trial of effect of a leukotriene receptor antagonist, montelukast, on tapering inhaled corticosteroids in asthmatic patients. <i>BMJ: British Medical Journal</i> , 1999, 319, 87-90.	2.3	227
10	Features of the bronchial bacterial microbiome associated with atopy, asthma, and responsiveness to inhaled corticosteroid treatment. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 140, 63-75.	2.9	222
11	Individualized therapy for persistent asthma in young children. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 138, 1608-1618.e12.	2.9	208
12	Efficacy and Safety of Itepekimab in Patients with Moderate-to-Severe Asthma. <i>New England Journal of Medicine</i> , 2021, 385, 1656-1668.	27.0	183
13	KIT Inhibition by Imatinib in Patients with Severe Refractory Asthma. <i>New England Journal of Medicine</i> , 2017, 376, 1911-1920.	27.0	159
14	Astegolimab (anti-ST2) efficacy and safety in adults with severe asthma: A randomized clinical trial. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 148, 790-798.	2.9	147
15	Thymic stromal lymphopoietin controls prostaglandin D <sub>2</sub> generation in patients with aspirin-exacerbated respiratory disease. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 137, 1566-1576.e5.	2.9	142
16	Alternative Macrophage Activation Is Increased in Asthma. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2016, 55, 467-475.	2.9	141
17	Effects of montelukast and beclomethasone on airway function and asthma control. <i>Journal of Allergy and Clinical Immunology</i> , 2002, 110, 847-854.	2.9	111
18	Integrating real-life studies in the global therapeutic research framework. <i>Lancet Respiratory Medicine</i> , 2013, 1, e29-e30.	10.7	102

#	ARTICLE	IF	CITATIONS
19	Effect of rare variants in ADRB2 on risk of severe exacerbations and symptom control during longacting $\beta_2$ agonist treatment in a multiethnic asthma population: a genetic study. <i>Lancet Respiratory Medicine</i> , 2014, 2, 204-213.	10.7	100
20	Bacterial biogeography of adult airways in atopic asthma. <i>Microbiome</i> , 2018, 6, 104.	11.1	93
21	Insulin resistance modifies the association between obesity and current asthma in adults. <i>European Respiratory Journal</i> , 2016, 48, 403-410.	6.7	92
22	Exhaled breath condensate eicosanoid levels associate with asthma and its severity. <i>Journal of Allergy and Clinical Immunology</i> , 2013, 132, 547-553.	2.9	89
23	Effects of Age and Disease Severity on Systemic Corticosteroid Responses in Asthma. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 195, 1439-1448.	5.6	87
24	Asthma Is More Severe in Older Adults. <i>PLoS ONE</i> , 2015, 10, e0133490.	2.5	80
25	Characteristics of Perimenstrual Asthma and Its Relation to Asthma Severity and Control. <i>Chest</i> , 2013, 143, 984-992.	0.8	78
26	Natural killer cell-mediated inflammation resolution is disabled in severe asthma. <i>Science Immunology</i> , 2017, 2, .	11.9	76
27	Inhaled Albuterol, but Not Intravenous Lidocaine, Protects Against Intubation-induced Bronchoconstriction in Asthma. <i>Anesthesiology</i> , 2000, 93, 1198-1204.	2.5	66
28	Racial disparities in asthma-related health care use in the National Heart, Lung, and Blood Institute's Severe Asthma Research Program. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 2052-2061.	2.9	65
29	Determinants of Exhaled Breath Condensate pH in a Large Population With Asthma. <i>Chest</i> , 2011, 139, 328-336.	0.8	61
30	Anticholinergic vs Long-Acting $\beta_2$ -Agonist in Combination With Inhaled Corticosteroids in Black Adults With Asthma. <i>JAMA - Journal of the American Medical Association</i> , 2015, 314, 1720.	7.4	61
31	Income is an independent risk factor for worse asthma outcomes. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 141, 754-760.e3.	2.9	59
32	The IL-33-PIN1-IRAK-M axis is critical for type 2 immunity in IL-33-induced allergic airway inflammation. <i>Nature Communications</i> , 2018, 9, 1603.	12.8	58
33	Impact of Age and Sex on Outcomes and Hospital Cost of Acute Asthma in the United States, 2011-2012. <i>PLoS ONE</i> , 2016, 11, e0157301.	2.5	57
34	Agonist-induced lipoxin A4 generation: Detection by a novel lipoxin A4-ELISA. <i>Lipids</i> , 1993, 28, 1047-1053.	1.7	54
35	Association Between Insomnia and Asthma Burden in the Severe Asthma Research Program (SARP) III. <i>Chest</i> , 2016, 150, 1242-1250.	0.8	51
36	Clinical Implications of Having Reduced Mid Forced Expiratory Flow Rates (FEF25-75), Independently of FEV1, in Adult Patients with Asthma. <i>PLoS ONE</i> , 2015, 10, e0145476.	2.5	49

#	ARTICLE	IF	CITATIONS
37	Distinct associations of sputum and oral microbiota with atopic, immunologic, and clinical features in mild asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 146, 1016-1026.	2.9	46
38	Impact of Age and Sex on Response to Asthma Therapy. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015, 192, 551-558.	5.6	45
39	Effect of ADRB2 polymorphisms on the efficacy of salmeterol and tiotropium in preventing COPD exacerbations: a prespecified substudy of the POET-COPD trial. <i>Lancet Respiratory Medicine</i> , 2014, 2, 44-53.	10.7	44
40	Reliever-Triggered Inhaled Glucocorticoid in Black and Latinx Adults with Asthma. <i>New England Journal of Medicine</i> , 2022, 386, 1505-1518.	27.0	40
41	Race is associated with differences in airway inflammation in patients with asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 140, 257-265.e11.	2.9	39
42	Mixed Sputum Granulocyte Longitudinal Impact on Lung Function in the Severe Asthma Research Program. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 203, 882-892.	5.6	39
43	Mucus Plugs Persist in Asthma, and Changes in Mucus Plugs Associate with Changes in Airflow over Time. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 205, 1036-1045.	5.6	39
44	Extrafine Versus Fine Inhaled Corticosteroids in Relation to Asthma Control: A Systematic Review and Meta-Analysis of Observational Real-Life Studies. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2018, 6, 907-915.e7.	3.8	36
45	Asthma and Corticosteroid Responses in Childhood and Adult Asthma. <i>Clinics in Chest Medicine</i> , 2019, 40, 163-177.	2.1	36
46	IL-13 Augments Compressive Stress-Induced Tissue Factor Expression in Human Airway Epithelial Cells. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2016, 54, 524-531.	2.9	35
47	A trial of type 12 purinergic (P2Y12) receptor inhibition with prasugrel identifies a potentially distinct endotype of patients with aspirin-exacerbated respiratory disease. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 316-324.e7.	2.9	34
48	Risk of pneumonia in obstructive lung disease: A real-life study comparing extra-fine and fine-particle inhaled corticosteroids. <i>PLoS ONE</i> , 2017, 12, e0178112.	2.5	31
49	Effect of COVID-19 on asthma exacerbation. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 2896-2899.e1.	3.8	31
50	A randomized, placebo-controlled trial evaluating effects of lebrikizumab on airway eosinophilic inflammation and remodelling in uncontrolled asthma (CLAVIER). <i>Clinical and Experimental Allergy</i> , 2020, 50, 1342-1351.	2.9	30
51	Quantitative CT metrics are associated with longitudinal lung function decline and future asthma exacerbations: Results from SARP-3. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 148, 752-762.	2.9	30
52	Genetics and the variability of treatment response in asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2005, 115, S532-S538.	2.9	29
53	ALX receptor ligands define a biochemical endotype for severe asthma. <i>JCI Insight</i> , 2017, 2, .	5.0	29
54	The endogenous circadian system worsens asthma at night independent of sleep and other daily behavioral or environmental cycles. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	7.1	28

#	ARTICLE	IF	CITATIONS
55	The Impact of Insulin Resistance on Loss of Lung Function and Response to Treatment in Asthma. American Journal of Respiratory and Critical Care Medicine, 2022, 206, 1096-1106.	5.6	28
56	Characterization of factors associated with systemic corticosteroid use in severe asthma: Data from the Severe Asthma Research Program. Journal of Allergy and Clinical Immunology, 2014, 133, 915-918.	2.9	27
57	<i>HSD3B1</i> genotype identifies glucocorticoid responsiveness in severe asthma. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 2187-2193.	7.1	27
58	PrecISE: Precision Medicine in Severe Asthma: An adaptive platform trial with biomarker ascertainment. Journal of Allergy and Clinical Immunology, 2021, 147, 1594-1601.	2.9	27
59	Asthma Yardstick. Annals of Allergy, Asthma and Immunology, 2017, 118, 133-142.e3.	1.0	26
60	Baseline sputum eosinophil <sup>+</sup> neutrophil subgroups <sup>â€™</sup> clinical characteristics and longitudinal trajectories for NHLBI Severe Asthma Research Program (SARP 3) cohort. Journal of Allergy and Clinical Immunology, 2020, 146, 222-226.	2.9	25
61	Preventing asthma in high risk kids (PARK) with omalizumab: Design, rationale, methods, lessons learned and adaptation. Contemporary Clinical Trials, 2021, 100, 106228.	1.8	24
62	The Precision Interventions for Severe and/or Exacerbation-Prone (PrecISE) Asthma Network: An overview of Network organization, procedures, and interventions. Journal of Allergy and Clinical Immunology, 2022, 149, 488-516.e9.	2.9	24
63	Plasma tryptase elevation during aspirin-induced reactions in aspirin-exacerbated respiratory disease. Journal of Allergy and Clinical Immunology, 2019, 143, 799-803.e2.	2.9	22
64	Genetic and non-genetic factors affecting the expression of COVID-19-relevant genes in the large airway epithelium. Genome Medicine, 2021, 13, 66.	8.2	21
65	Update on reslizumab for eosinophilic asthma. Expert Opinion on Biological Therapy, 2015, 15, 1531-1539.	3.1	20
66	Development and initial validation of the Asthma Severity Scoring System (ASSESS). Journal of Allergy and Clinical Immunology, 2020, 145, 127-139.	2.9	19
67	Comparing the effectiveness of small-particle versus large-particle inhaled corticosteroid in COPD. International Journal of COPD, 2014, 9, 1163.	2.3	18
68	Real-life effectiveness of mepolizumab in severe asthma: a systematic literature review. Journal of Asthma, 2022, 59, 2201-2217.	1.7	18
69	A randomized, open-label, pragmatic study to assess reliever-triggered inhaled corticosteroid in African American/Black and Hispanic/Latinx adults with asthma: Design and methods of the PREPARE trial. Contemporary Clinical Trials, 2021, 101, 106246.	1.8	14
70	Responsiveness to Parenteral Corticosteroids and Lung Function Trajectory in Adults with Moderate-to-Severe Asthma. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 841-852.	5.6	14
71	Deconstructing the Way We Use Pulmonary Function Test Race-Based Adjustments. Journal of Allergy and Clinical Immunology: in Practice, 2022, 10, 972-978.	3.8	13
72	Geography, generalisability, and susceptibility in clinical trials. Lancet Respiratory Medicine, the, 2021, 9, 330-332.	10.7	12

#	ARTICLE	IF	CITATIONS
73	Add-on LABA in a separate inhaler as asthma step-up therapy <i>versus</i> increased dose of ICS or ICS/LABA combination inhaler. ERJ Open Research, 2016, 2, 00106-2015.	2.6	11
74	The precision interventions for severe and/or exacerbation-prone asthma (PreCISE) adaptive platform trial: statistical considerations. Journal of Biopharmaceutical Statistics, 2020, 30, 1026-1037.	0.8	11
75	Eosinophilâ€derived neurotoxin and clinical outcomes with mepolizumab in severe eosinophilic asthma. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 2085-2088.	5.7	11
76	The association of plasma IL-6 with measures of asthma morbidity in a moderate-severe pediatric cohort aged 6-18 years. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 2916-2919.e2.	3.8	11
77	Implementing the guidelines: What do you do when the rubber hits the road?. Journal of Allergy and Clinical Immunology, 2020, 146, 1271-1274.	2.9	10
78	Adherence to adding inhaled corticosteroids to rescue therapy in a pragmatic trial with adults with asthma. Annals of Allergy, Asthma and Immunology, 2020, 124, 487-493.e1.	1.0	8
79	Vitamin D3 treatment of vitamin Dâ€insufficient asthmatic patients does not alter immune cell function. Journal of Allergy and Clinical Immunology, 2016, 138, 286-289.e9.	2.9	7
80	Association of free vitamin D3 concentrations and asthma treatment failures in the VIDA Trial. Annals of Allergy, Asthma and Immunology, 2018, 121, 444-450.e1.	1.0	7
81	Increased extracellular maspin levels after mechanical compression inâvitro or allergen challenge inâvivo. Journal of Allergy and Clinical Immunology, 2019, 144, 1116-1118.e4.	2.9	6
82	Loss of bronchoprotection with ICS plus LABA treatment, Î²-receptor dynamics, and the effect of alendronate. Journal of Allergy and Clinical Immunology, 2019, 144, 416-425.e7.	2.9	6
83	Flexibility and strength training in asthma: A pilot study. Journal of Asthma, 2018, 55, 1376-1383.	1.7	5
84	Compressive Stress Causes an Unjamming Transition and an Epithelialâ€Mesenchymal Transition in the Airway Epithelium in Asthma. Annals of the American Thoracic Society, 2016, 13, S102-S102.	3.2	5
85	Susceptibility to exacerbations in Black adults with asthma. Journal of Asthma, 2019, 56, 704-710.	1.7	4
86	Adapting clinical trial design to maintain meaningful outcomes during a multicenter asthma trial in the precision medicine era. Contemporary Clinical Trials, 2019, 77, 98-103.	1.8	4
87	Estimated Ventricular Size, Asthma Severity,âand Exacerbations. Chest, 2020, 157, 258-267.	0.8	4
88	Real-world experiences with generating real-world evidence: Case Studies from PCORI's pragmatic clinical Studies program. Contemporary Clinical Trials, 2020, 98, 106171.	1.8	4
89	Nebulizer Use by Black and Latinx Adults with Moderate to Severe Asthma. Journal of Allergy and Clinical Immunology: in Practice, 2022, 10, 517-524.e2.	3.8	4
90	Socioeconomic impact of COVID-19 and willingness to be vaccinated in African American/Black and Hispanic/Latinx adults. Journal of the National Medical Association, 2022, 114, 182-192.	0.8	4

#	ARTICLE	IF	CITATIONS
91	LTC4 synthase polymorphism modifies efficacy of botanical seed oil combination in asthma. SpringerPlus, 2014, 3, 661.	1.2	3
92	Anti-IgE or Anti-IL5: That Is the Question. Journal of Allergy and Clinical Immunology: in Practice, 2018, 6, 782-784.	3.8	3
93	Nocturnal bilevel positive airway pressure for the treatment of asthma. Respiratory Physiology and Neurobiology, 2020, 274, 103355.	1.6	3
94	Severe Asthma: Pragmatic Clinical Lumping and Time for Investigational Splitting. American Journal of Respiratory and Critical Care Medicine, 2014, 189, 619-620.	5.6	2
95	Biologics, Clinical Context, and the Asthmas. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 1437-1439.	3.8	2
96	Challenges in assessing the efficacy of systemic corticosteroids for severe wheezing episodes in preschool children. Journal of Allergy and Clinical Immunology, 2019, 143, 1934-1937.e4.	2.9	2
97	Asthma Step-Down Strategies: Perhaps the Patient Should Decide?. Journal of Allergy and Clinical Immunology: in Practice, 2018, 6, 644-645.	3.8	1
98	What Patients Can Tell Us About Their Asthma. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 906-907.	3.8	1
99	Personalizing Precision Medicine. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 1614-1615.	3.8	1
100	Mechanisms and Treatment of the Diverse Presentations of Acute Wheezing and Asthma. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 2635-2637.	3.8	1
101	Reply. Journal of Allergy and Clinical Immunology, 2019, 144, 873-874.	2.9	0
102	Predictors of inhaled corticosteroid taper failure in adults with asthma. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 1335-1337.e3.	3.8	0
103	Key Issues in Pediatric and Adult Severe Asthma: Staying Grounded as Biologics Take Us to New Heights. Journal of Allergy and Clinical Immunology: in Practice, 2022, 10, 420-421.	3.8	0